Mechanisms of resistance to EGFR tyrosine kinase inhibitors

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lihua, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629442/
https://www.ncbi.nlm.nih.gov/pubmed/26579470
http://dx.doi.org/10.1016/j.apsb.2015.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629442/
https://www.ncbi.nlm.nih.gov/pubmed/26579470
http://dx.doi.org/10.1016/j.apsb.2015.07.001

Ejemplares similares